The cost impact of disease progression to metastatic castration-sensitive prostate cancer

Trinh, Quoc‐Dien; Chaves, Leonardo Passos; Feng, Qi; Zhu, Julia; Sandin, Rickard; Abbott, T. D.

doi:10.18553/jmcp.2022.28.5.544

Cited by 2 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies evaluating the cost of metastatic prostate cancer treatment in the privately insured population typically document a higher cost burden compared with that in the Medicare population. A recent study of the MarketScan data from 2014 to 2016—a subset of our study period—estimated the lifetime incremental cost of metastatic prostate cancer treatment in the commercial population at $82,336 for those previously diagnosed with localized disease and $161,714 for those diagnosed with de novo metastatic disease, both expressed in 2018 US dollars 26 . By using newer data from 2016 to 2019, another study compared the treatment cost of nonmetastatic versus metastatic, castration‐resistant prostate cancer, concluding that the mean incremental cost to payers was $113,725 27 .…”

Section: Discussionmentioning

confidence: 99%

“…for those diagnosed with de novo metastatic disease, both expressed in 2018 US dollars. 26 By using newer data from 2016 to 2019, another study compared the treatment cost of nonmetastatic versus metastatic, castration-resistant prostate cancer, concluding that the mean incremental cost to payers was $113,725. 27 However, that analysis focused only on patients with prostate cancer undergoing androgen-deprivation therapy, and thus these results may not generalize to different disease-management approaches.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The cost burden of metastatic prostate cancer in the US populations covered by employer‐sponsored health insurance

Horný

Yabroff

Filson

et al. 2023

Cancer

View full text Add to dashboard Cite

BackgroundRecent advancements in the clinical management of metastatic prostate cancer include several costly therapies and diagnostic tests. The objective of this study was to provide updated information on the cost to payers attributable to metastatic prostate cancer among men aged 18 to 64 years with employer‐sponsored health plans and men aged 18 years or older covered by employer‐sponsored Medicare supplement insurance.MethodsBy using Merative MarketScan commercial and Medicare supplemental data for 2009–2019, the authors calculated differences in spending between men with metastatic prostate cancer and their matched, prostate cancer‐free controls, adjusting for age, enrollment length, comorbidities, and inflation to 2019 US dollars.ResultsThe authors compared 9011 patients who had metastatic prostate cancer and were covered by commercial insurance plans with a group of 44,934 matched controls and also compared 17,899 patients who had metastatic prostate cancer and were covered by employer‐sponsored Medicare supplement plans with a group of 87,884 matched controls. The mean age of patients with metastatic prostate cancer was 58.5 years in the commercial samples and 77.8 years in the Medicare supplement samples. Annual spending attributable to metastatic prostate cancer was $55,949 per person‐year (95% confidence interval [CI], $54,074–$57,825 per person‐year) in the commercial population and $43,682 per person‐year (95% CI, $42,022–$45,342 per person‐year) in the population covered by Medicare supplement plans, both in 2019 US dollars.ConclusionsThe cost burden attributable to metastatic prostate cancer exceeds $55,000 per person‐year among men with employer‐sponsored health insurance and $43,000 among those covered by employer‐sponsored Medicare supplement plans. These estimates can improve the precision of value assessments of clinical and policy approaches to the prevention, screening, and treatment of prostate cancer in the United States.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%